Global Nanostructured Drug

Nanostructured Drug Comprehensive Study by Type (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion and Nanoemulsion, Nanosuspension), Application (Cardiovascular/Chronic, Immunology, Neurology, Oncology/Cancer Treatment, Others), Distribution Channel (Direct Channel, Indirect Channel) Players and Region - Global Market Outlook to 2030

Nanostructured Drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 9.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Nanostructured Drug Market Scope
Nanotechnology introduces exciting prospectus in the field of Medical science. A nanostructured drug is the application of nanotechnology to drug manufacturing. Nanostructured drugs are referred to as a nano-drug delivery system. Nanoparticles are more efficient at the cellular and molecular level which will transcend to their better working than traditional drugs. The field of nanostructured drugs is experiencing immense investments specifically focused on its research and development. Especially these investments have seen a boost since the pandemic because of the high accuracy of nanotechnology in the detection and treatment of viruses.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAstraZeneca Plc (United Kingdom), GlaxoSmithKline (United Kingdom), Merck & Co. Inc. (United States), Pfizer Inc. (United States), Moderna, Inc. (United States), Sanofi Pharma (France), Novo Nordisk (Denmark), NanoViricides, Inc. (United States), Johnson and Johnson (United States), Mistsubishi Tanabe Pharma Corporation (Japan) and Celgene Corporation (United States)
CAGR9.4%


The market is new with big pharmaceutical players as well as new startups in biotech flooding the market with innovation. Pfizer Inc. and Moderna Inc. are currently leading the use of nanostructured drugs since they both bought in use of lipid nanoparticles in their Covid-19 Vaccines respectively. Thus with the increase in health investments by governments around the world will also draw huge funds to innovations and research in nanostructured drugs bringing huge prospectus for the growth of this market Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Nanostructured Drug market throughout the predicted period.

AstraZeneca Plc (United Kingdom), GlaxoSmithKline (United Kingdom), Merck & Co. Inc. (United States), Pfizer Inc. (United States), Moderna, Inc. (United States), Sanofi Pharma (France), Novo Nordisk (Denmark), NanoViricides, Inc. (United States), Johnson and Johnson (United States), Mistsubishi Tanabe Pharma Corporation (Japan) and Celgene Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Taiwan Liposome Co., Eli Lilly and Company (United States) and NanoCarrier Co., Ltd (Japan).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Nanostructured Drug market by Type , by Application (Cardiovascular/Chronic, Immunology, Neurology, Oncology/Cancer Treatment and Others) and Region with country level break-up.

On the basis of geography, the market of Nanostructured Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In 2020, Swiss pharmaceutical giant Novartis AG announced the completion of the acquisition of The Medicines Company, with this deal Novartis looks at expanding its line of cardiovascular disease solutions
In 2020, Pfizer Inc. launched BioNTech COVID-19 vaccine based on mRNA technology which will use lipid nanoparticles to protect and transport the vaccine component in the human body


Influencing Trend:
Nano-Structured Drugs are Being Innovated to Combat Viruses Because of Better Cellular and Molecular Reach of Nano Particles than Macro Particles

Market Growth Drivers:
Increase in Chronic and Cardiovascular Diseases have led to Rising Innovation, Research & Development and Demand for Nanostructured Drugs and Efficacy of Nanostructured Drug is more than Traditional Drugs

Challenges:
The Nanostructured Drugs is Still in its Beginning Stages with More Research Needed to Understand the Limitations and Barriers of Nanostructured Drugs in Human Body, Nanostructured Drugs has Great Prospectus But it will Exhibit Challenge for Scientists to Apply it Practically and Complexity in Manufacturing and thus the High Cost Involved with it, Leads to Overall High Costs of Nanostructured Drugs Compared to Traditional Drugs

Restraints:
FDA and Euro Regulations Always were Stringent with Regards to Drugs regulations, thus Nanostructured Drugs Being No Exception would Face Delay in the Roll Out or Manufacturing of New Nanostructured Drugs

Opportunities:
One Dimensional Nanomaterial Open a Wide Array of New Unexplored Opportunities for Nanostructured Drugs Manufacturers

Key Target Audience
Nanostructured drug manufacturers, Suppliers, and Distributors, API Suppliers, New Entrants/Investors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-User Industries

Report Objectives / Segmentation Covered

By Type
  • Liposomes
  • Polymeric Micelles
  • Solid Lipid Nanoparticles
  • Microemulsion and Nanoemulsion
  • Nanosuspension
By Application
  • Cardiovascular/Chronic
  • Immunology
  • Neurology
  • Oncology/Cancer Treatment
  • Others
By Distribution Channel
  • Direct Channel
  • Indirect Channel

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Chronic and Cardiovascular Diseases have led to Rising Innovation, Research & Development and Demand for Nanostructured Drugs
      • 3.2.2. Efficacy of Nanostructured Drug is more than Traditional Drugs
    • 3.3. Market Challenges
      • 3.3.1. The Nanostructured Drugs is Still in its Beginning Stages with More Research Needed to Understand the Limitations and Barriers of Nanostructured Drugs in Human Body
      • 3.3.2. Nanostructured Drugs has Great Prospectus But it will Exhibit Challenge for Scientists to Apply it Practically
      • 3.3.3. Complexity in Manufacturing and thus the High Cost Involved with it, Leads to Overall High Costs of Nanostructured Drugs Compared to Traditional Drugs
    • 3.4. Market Trends
      • 3.4.1. Nano-Structured Drugs are Being Innovated to Combat Viruses Because of Better Cellular and Molecular Reach of Nano Particles than Macro Particles
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nanostructured Drug, by Type, Application, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nanostructured Drug (Value)
      • 5.2.1. Global Nanostructured Drug by: Type (Value)
        • 5.2.1.1. Liposomes
        • 5.2.1.2. Polymeric Micelles
        • 5.2.1.3. Solid Lipid Nanoparticles
        • 5.2.1.4. Microemulsion and Nanoemulsion
        • 5.2.1.5. Nanosuspension
      • 5.2.2. Global Nanostructured Drug by: Application (Value)
        • 5.2.2.1. Cardiovascular/Chronic
        • 5.2.2.2. Immunology
        • 5.2.2.3. Neurology
        • 5.2.2.4. Oncology/Cancer Treatment
        • 5.2.2.5. Others
      • 5.2.3. Global Nanostructured Drug by: Distribution Channel (Value)
        • 5.2.3.1. Direct Channel
        • 5.2.3.2. Indirect Channel
      • 5.2.4. Global Nanostructured Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Nanostructured Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca Plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Moderna, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi Pharma (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novo Nordisk (Denmark)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NanoViricides, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson and Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mistsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Celgene Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Nanostructured Drug Sale, by Type, Application, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nanostructured Drug (Value)
      • 7.2.1. Global Nanostructured Drug by: Type (Value)
        • 7.2.1.1. Liposomes
        • 7.2.1.2. Polymeric Micelles
        • 7.2.1.3. Solid Lipid Nanoparticles
        • 7.2.1.4. Microemulsion and Nanoemulsion
        • 7.2.1.5. Nanosuspension
      • 7.2.2. Global Nanostructured Drug by: Application (Value)
        • 7.2.2.1. Cardiovascular/Chronic
        • 7.2.2.2. Immunology
        • 7.2.2.3. Neurology
        • 7.2.2.4. Oncology/Cancer Treatment
        • 7.2.2.5. Others
      • 7.2.3. Global Nanostructured Drug by: Distribution Channel (Value)
        • 7.2.3.1. Direct Channel
        • 7.2.3.2. Indirect Channel
      • 7.2.4. Global Nanostructured Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nanostructured Drug: by Type(USD Million)
  • Table 2. Nanostructured Drug Liposomes , by Region USD Million (2018-2023)
  • Table 3. Nanostructured Drug Polymeric Micelles , by Region USD Million (2018-2023)
  • Table 4. Nanostructured Drug Solid Lipid Nanoparticles , by Region USD Million (2018-2023)
  • Table 5. Nanostructured Drug Microemulsion and Nanoemulsion , by Region USD Million (2018-2023)
  • Table 6. Nanostructured Drug Nanosuspension , by Region USD Million (2018-2023)
  • Table 7. Nanostructured Drug: by Application(USD Million)
  • Table 8. Nanostructured Drug Cardiovascular/Chronic , by Region USD Million (2018-2023)
  • Table 9. Nanostructured Drug Immunology , by Region USD Million (2018-2023)
  • Table 10. Nanostructured Drug Neurology , by Region USD Million (2018-2023)
  • Table 11. Nanostructured Drug Oncology/Cancer Treatment , by Region USD Million (2018-2023)
  • Table 12. Nanostructured Drug Others , by Region USD Million (2018-2023)
  • Table 13. Nanostructured Drug: by Distribution Channel(USD Million)
  • Table 14. Nanostructured Drug Direct Channel , by Region USD Million (2018-2023)
  • Table 15. Nanostructured Drug Indirect Channel , by Region USD Million (2018-2023)
  • Table 16. South America Nanostructured Drug, by Country USD Million (2018-2023)
  • Table 17. South America Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 18. South America Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 19. South America Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 20. Brazil Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 21. Brazil Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 22. Brazil Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 23. Argentina Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 24. Argentina Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 25. Argentina Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 26. Rest of South America Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 29. Asia Pacific Nanostructured Drug, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 33. China Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 34. China Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 35. China Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 36. Japan Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 37. Japan Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 38. Japan Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 39. India Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 40. India Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 41. India Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 42. South Korea Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 43. South Korea Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 44. South Korea Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 45. Taiwan Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 46. Taiwan Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 47. Taiwan Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 48. Australia Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 49. Australia Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 50. Australia Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 54. Europe Nanostructured Drug, by Country USD Million (2018-2023)
  • Table 55. Europe Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 56. Europe Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 57. Europe Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 58. Germany Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 59. Germany Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 60. Germany Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 61. France Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 62. France Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 63. France Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 64. Italy Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 65. Italy Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 66. Italy Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 67. United Kingdom Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 70. Netherlands Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 71. Netherlands Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 72. Netherlands Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 73. Rest of Europe Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 76. MEA Nanostructured Drug, by Country USD Million (2018-2023)
  • Table 77. MEA Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 78. MEA Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 79. MEA Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 80. Middle East Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 81. Middle East Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 82. Middle East Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 83. Africa Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 84. Africa Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 85. Africa Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 86. North America Nanostructured Drug, by Country USD Million (2018-2023)
  • Table 87. North America Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 88. North America Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 89. North America Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 90. United States Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 91. United States Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 92. United States Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 93. Canada Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 94. Canada Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 95. Canada Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 96. Mexico Nanostructured Drug, by Type USD Million (2018-2023)
  • Table 97. Mexico Nanostructured Drug, by Application USD Million (2018-2023)
  • Table 98. Mexico Nanostructured Drug, by Distribution Channel USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Nanostructured Drug: by Type(USD Million)
  • Table 111. Nanostructured Drug Liposomes , by Region USD Million (2025-2030)
  • Table 112. Nanostructured Drug Polymeric Micelles , by Region USD Million (2025-2030)
  • Table 113. Nanostructured Drug Solid Lipid Nanoparticles , by Region USD Million (2025-2030)
  • Table 114. Nanostructured Drug Microemulsion and Nanoemulsion , by Region USD Million (2025-2030)
  • Table 115. Nanostructured Drug Nanosuspension , by Region USD Million (2025-2030)
  • Table 116. Nanostructured Drug: by Application(USD Million)
  • Table 117. Nanostructured Drug Cardiovascular/Chronic , by Region USD Million (2025-2030)
  • Table 118. Nanostructured Drug Immunology , by Region USD Million (2025-2030)
  • Table 119. Nanostructured Drug Neurology , by Region USD Million (2025-2030)
  • Table 120. Nanostructured Drug Oncology/Cancer Treatment , by Region USD Million (2025-2030)
  • Table 121. Nanostructured Drug Others , by Region USD Million (2025-2030)
  • Table 122. Nanostructured Drug: by Distribution Channel(USD Million)
  • Table 123. Nanostructured Drug Direct Channel , by Region USD Million (2025-2030)
  • Table 124. Nanostructured Drug Indirect Channel , by Region USD Million (2025-2030)
  • Table 125. South America Nanostructured Drug, by Country USD Million (2025-2030)
  • Table 126. South America Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 127. South America Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 128. South America Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 129. Brazil Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 130. Brazil Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 131. Brazil Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 132. Argentina Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 133. Argentina Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 134. Argentina Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 135. Rest of South America Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 136. Rest of South America Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 137. Rest of South America Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 138. Asia Pacific Nanostructured Drug, by Country USD Million (2025-2030)
  • Table 139. Asia Pacific Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 140. Asia Pacific Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 141. Asia Pacific Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 142. China Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 143. China Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 144. China Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 145. Japan Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 146. Japan Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 147. Japan Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 148. India Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 149. India Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 150. India Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 151. South Korea Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 152. South Korea Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 153. South Korea Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 154. Taiwan Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 155. Taiwan Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 156. Taiwan Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 157. Australia Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 158. Australia Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 159. Australia Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 163. Europe Nanostructured Drug, by Country USD Million (2025-2030)
  • Table 164. Europe Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 165. Europe Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 166. Europe Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 167. Germany Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 168. Germany Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 169. Germany Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 170. France Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 171. France Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 172. France Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 173. Italy Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 174. Italy Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 175. Italy Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 176. United Kingdom Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 177. United Kingdom Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 178. United Kingdom Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 179. Netherlands Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 180. Netherlands Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 181. Netherlands Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 182. Rest of Europe Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 183. Rest of Europe Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 184. Rest of Europe Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 185. MEA Nanostructured Drug, by Country USD Million (2025-2030)
  • Table 186. MEA Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 187. MEA Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 188. MEA Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 189. Middle East Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 190. Middle East Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 191. Middle East Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 192. Africa Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 193. Africa Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 194. Africa Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 195. North America Nanostructured Drug, by Country USD Million (2025-2030)
  • Table 196. North America Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 197. North America Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 198. North America Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 199. United States Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 200. United States Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 201. United States Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 202. Canada Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 203. Canada Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 204. Canada Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 205. Mexico Nanostructured Drug, by Type USD Million (2025-2030)
  • Table 206. Mexico Nanostructured Drug, by Application USD Million (2025-2030)
  • Table 207. Mexico Nanostructured Drug, by Distribution Channel USD Million (2025-2030)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nanostructured Drug: by Type USD Million (2018-2023)
  • Figure 5. Global Nanostructured Drug: by Application USD Million (2018-2023)
  • Figure 6. Global Nanostructured Drug: by Distribution Channel USD Million (2018-2023)
  • Figure 7. South America Nanostructured Drug Share (%), by Country
  • Figure 8. Asia Pacific Nanostructured Drug Share (%), by Country
  • Figure 9. Europe Nanostructured Drug Share (%), by Country
  • Figure 10. MEA Nanostructured Drug Share (%), by Country
  • Figure 11. North America Nanostructured Drug Share (%), by Country
  • Figure 12. Global Nanostructured Drug share by Players 2023 (%)
  • Figure 13. Global Nanostructured Drug share by Players (Top 3) 2023(%)
  • Figure 14. Global Nanostructured Drug share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. AstraZeneca Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. AstraZeneca Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Moderna, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Moderna, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Sanofi Pharma (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi Pharma (France) Revenue: by Geography 2023
  • Figure 28. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 29. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 30. NanoViricides, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. NanoViricides, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson and Johnson (United States) Revenue: by Geography 2023
  • Figure 34. Mistsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Mistsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2023
  • Figure 36. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 37. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 38. Global Nanostructured Drug: by Type USD Million (2025-2030)
  • Figure 39. Global Nanostructured Drug: by Application USD Million (2025-2030)
  • Figure 40. Global Nanostructured Drug: by Distribution Channel USD Million (2025-2030)
  • Figure 41. South America Nanostructured Drug Share (%), by Country
  • Figure 42. Asia Pacific Nanostructured Drug Share (%), by Country
  • Figure 43. Europe Nanostructured Drug Share (%), by Country
  • Figure 44. MEA Nanostructured Drug Share (%), by Country
  • Figure 45. North America Nanostructured Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AstraZeneca Plc (United Kingdom)
  • GlaxoSmithKline (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Pfizer Inc. (United States)
  • Moderna, Inc. (United States)
  • Sanofi Pharma (France)
  • Novo Nordisk (Denmark)
  • NanoViricides, Inc. (United States)
  • Johnson and Johnson (United States)
  • Mistsubishi Tanabe Pharma Corporation (Japan)
  • Celgene Corporation (United States)
Additional players considered in the study are as follows:
Taiwan Liposome Co. , Eli Lilly and Company (United States) , NanoCarrier Co., Ltd (Japan) ,
Select User Access Type

Key Highlights of Report


Apr 2024 243 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nanostructured Drug Quantitative research analysis
Global Nanostructured Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Nanostructured Drug Market are by type [Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion and Nanoemulsion and Nanosuspension], by end use application [Cardiovascular/Chronic, Immunology, Neurology, Oncology/Cancer Treatment and Others].
The Nanostructured Drug Market is gaining popularity and expected to see strong valuation by 2030.
  • Increase in Chronic and Cardiovascular Diseases have led to Rising Innovation, Research & Development and Demand for Nanostructured Drugs
  • Efficacy of Nanostructured Drug is more than Traditional Drugs

Know More About Global Nanostructured Drug Report?

Have a Query? Click Here

Other Related Reports

Vegetable Capsules Comprehensive Study by Type (HPMC with Gelling Agent, HPMC without Gelling Agent, Plant Polysaccarides, Starch, Pullulan), Application (Supplements, Medicine, Cosmetics), End Use...
$ 3450
Angioedema Treatment Comprehensive Study by Type (Antihistamines, Corticosteroids, Others), Application (Hospitals, Clinics, Research Organizations ), Drugs (C1 Esterase Inhibitor, Selective Bradykin...
$ 3450
Sodium Chloride Injection Comprehensive Study by Application (Hospitals, Clinics, Other Medical Institutions), Container (Flexible Bag, Plastic Bottles, Glass Bottles), Distribution Channel (Online, ...
$ 3500
Lactulose Concentrate Comprehensive Study by Type (Chemical Synthesis, Enzymatic Method), Application (Pharmaceuticals, Food Industry, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Calcitonin Injection Comprehensive Study by Type (Elcatonin Injection, Salmon Calcitonin Injection), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Regio...
$ 3500
Naltrexone HCl Comprehensive Study by Type (Tablet, Capsule), Application (Alcohol Independence, Opioid Independence, Others), Distribution Channel (Hospital, Pharmacies) Players and Region - Global ...
$ 3500